摘要
Objective:Camellia nitidissima Chi,a Chinese medicine commonly used by ethnic minorities in Guangxi,China,is beneficial for clearing heat,detoxifying,inducing diuresis,and suppressing swelling.It has various pharmacological properties,including antitumor,anti-inflammatory,and antioxidant.However,its potential application in radioprotection remains unclear.In this study,we aimed to determine whether Camellia nitidissima Chi has radioprotective effects against radiation-induced gastrointestinal and hematopoietic damage.Methods:The 1,1-diphenyl-2-picrylhydrazyl(DPPH)free radical and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)(ABTS)techniques were used to assess the ability of Camellia nitidissima Chi to scavenge free radicals.We conducted a 30-day survival rate experiment to evaluate the radioprotective capabilities of Camellia nitidissima Chi.Additionally,we developed models of radiation-induced intestinal and hematopoietic damage.Alterations in the white blood cell(WBC)count,total superoxide dismutase(T-SOD),glutathione(GSH),and protein expression linked to apoptosis were observed.Results:Camellia nitidissima Chi scavenged 84.72%and 93.47%of DPPH and ABTS,had a certain radiation protection potential,and increased the survival rate of mice to over 90%.Moreover,following exposure,Camellia nitidissima Chi enhanced WBC,T-SOD,and GSH levels.Camellia nitidissima Chi increased B-cell lymphoma-extra large(BCL-XL)expression and suppressed Bcl-2 associated X protein(BAX)expression,providing radioprotection to cells.Conclusions:Camellia nitidissima Chi has a strong antioxidant ability;it can improve the survival rate of mice after lethal dose irradiation and protect against radiation-induced hematopoietic and gastrointestinal damage.These findings can serve as a guide for using Chinese medicines for radioprotection.
基金
sponsored by the National Natural Science Foundation of China(82303681 and 82202950)
Fundamental Research Funds for the Central Universities(3332022063)
the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2021-I2M-1-042)
The National Natural Science Foundation of China(82202950)
the Fundamental Research Funds for the Central Universities(3332022063)
Feifei Xu,who participated in the research design.The National Natural Science Foundation of China(82303681)
Wenfeng Gou,who participated in the research design
The Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2021-I2M-1-042)
Wenbin Hou,who designed and conceived the study.
作者简介
Zhiyun Wang and Haihua Shang contributed equally to this work and share first authorship;Corresponding author:Wei Li,E-mail:liwei@phar.toho-u.ac.jp;Corresponding author:Yuefei Wang,E-mail:wangyf0622@tjutcm.edu.cn;Corresponding author:Wenbin Hou,E-mail:houwenbin@irm-cams.ac.cn.
